X

Drug Profile

LY 518674

Alternative Names: LY 674; LY518674

Latest Information Update: 05 Nov 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eli Lilly and Company; Ligand Pharmaceuticals
Class Antihyperglycaemics; Antihyperlipidaemics
Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Atherosclerosis; Lipid metabolism disorders

Most Recent Events

23 Mar 2009 Discontinued - Phase-I for Lipid metabolism disorders in USA (PO)
23 Mar 2009 Discontinued - Phase-II for Atherosclerosis in USA (PO)
11 Apr 2007 Data presented at the 56th Annual Scientific Session of the American College of Cardiology (ACC-2007) have been added to the adverse events and Hyperlipidaemia therapeutic trials sections ,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com